By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

Women over 40 face a higher risk of chronic lung disease, possibly due to indoor pollution, hormonal shifts, and misdiagnosis ...

For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a recent study.

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.